Results 101 to 110 of about 2,704,633 (236)

Prothrombin Complex Concentrate Such as Therapy and Prophylaxis in Factor X-Deficient Patient (Friuli Variant)

, 2010
Giovanni Barillari, Samantha Pasca, Nevio Gonano, Roberto Daminato   +3 more
openalex   +2 more sources

Detecting falls with X-Factor Hidden Markov Models [PDF]

, 2017
Shehroz S. Khan, Michelle Karg, Dana Kulić, Jesse Hoey   +3 more
openalex   +1 more source

CDK11 inhibition induces cytoplasmic p21WAF1 splice variant by p53 stabilisation and SF3B1 inactivation

Molecular Oncology, EarlyView.
CDK11 inhibition stabilises the tumour suppressor p53 and triggers the production of an alternative p21WAF1 splice variant p21L, through the inactivation of the spliceosomal protein SF3B1. Unlike the canonical p21WAF1 protein, p21L is localised in the cytoplasm and has reduced cell cycle‐blocking activity.
Radovan Krejcir, Lukasz Arcimowicz, Lucia Martinkova, Vaclav Hrabal, Filip Zavadil Kokas, Tomas Henek, Martina Kucerikova, Ondrej Bonczek, Pavlina Zatloukalova, Lenka Hernychova, Philip J. Coates, Borivoj Vojtesek, David P. Lane   +12 more
wiley   +1 more source

The Factors of (a, b, c, f, g, h)(x, y, z)²–λ(x²+y²+z²) [PDF]

, 1909
Robert J. Bell
openalex   +1 more source

Reduced vascular leakage correlates with breast carcinoma T regulatory cell infiltration but not with metastatic propensity

Molecular Oncology, EarlyView.
A mouse model for vascular normalization and a human breast cancer cohort were studied to understand the relationship between vascular leakage and tumor immune suppression. For this, endothelial and immune cell RNAseq, staining for vascular function, and immune cell profiling were employed.
Liqun He, Chiara Testini, Neda Hekmati, Altea Bonello, Aglaia Schiza, Emmanuel Nwadozi, Mia Phillipson, Carina Strell, Michael Welsh   +8 more
wiley   +1 more source

Genotype x environment interaction in cassava multi-environment trials via analytic factor.

PLoS ONE
The variability in genetic variance and covariance due to genotype × environment interaction (G×E) can hinder genotype selection accuracy, especially for complex traits.
Juraci Souza Sampaio Filho, Isadora Cristina Martins Oliveira, Maria Marta Pastina, Marcos de Souza Campos, Eder Jorge de Oliveira   +4 more
doaj   +1 more source

Pink-beam serial femtosecond crystallography for accurate structure factor determination at an X-ray free-electron laser [PDF]

, 2021
Karol Nass, Camila Bacellar, Claudio Cirelli, Florian Dworkowski, Y. Gevorkov, Daniel James, Philip J. M. Johnson, Demet Kekilli, Gregor Knopp, Isabelle Martiel, D. Ozerov, A. Tolstikova, Laura Vera, Tobias Weinert, Oleksandr Yefanov, Jörg Standfuss, S. Reiche, Christopher J. Milne   +17 more
openalex   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

A review of the pharmacokinetics, efficacy and safety of high-purity factor X for the prophylactic treatment of hereditary factor X deficiency. [PDF]

Haemophilia, 2022
Payne J, Batsuli G, Leavitt AD, Mathias M, McGuinn CE.   +4 more
europepmc   +1 more source